Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (≥10%) Well-Differentiated Endocrine Carcinoma Staging | Zendy

Ronan Abgral | Zendy; Sophie Leboulleux | Zendy; Désirèe Deandreis | Zendy; Anne Aupérin | Zendy; J. Lumbroso | Zendy; Clarisse Dromain | Zendy; Pierre Duvillard | Zendy; Dominique Élias | Zendy; Thierry de Baère | Zendy; J. Guigay | Zendy; Michel Ducreux | Zendy; Martin Schlumberger | Zendy; Éric Baudin | Zendy

Open Access

Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (≥10%) Well-Differentiated Endocrine Carcinoma Staging

Author(s) -

Ronan Abgral,

Sophie Leboulleux,

Désirèe Deandreis,

Anne Aupérin,

J. Lumbroso,

Clarisse Dromain,

Pierre Duvillard,

Dominique Élias,

Thierry de Baère,

J. Guigay,

Michel Ducreux,

Martin Schlumberger,

Éric Baudin

Publication year - 2010

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2010-2022

Subject(s) - medicine , positron emission tomography , nuclear medicine , standardized uptake value , somatostatin receptor , lesion , scintigraphy , endocrine system , prospective cohort study , octreotide , radiology , somatostatin , pathology , hormone

The purpose of this prospective study was to compare the performance of (111)In-octreotide somatostatin receptor scintigraphy (SRS) and (18)fluorodesoxyglucose positron emission tomography (FDG-PET) in aggressive well-differentiated endocrine carcinoma (WDEC) defined by a high Ki67 (≥10%).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research